Inflammatory pathways and potential therapies for COVID-19: A mini review

Abstract

The public health crisis of the novel coronavirus disease (COVID-19) is alarming since January 2020. COVID-19 genome (SARS-CoV-2) is related to other highly pathogenic coronaviruses SARS-CoV (severe acute respiratory syndrome coronavirus) and MERS-CoV (Middle East respiratory syndrome coronavirus). Amino acid substitutions in some of SARS-CoV-2 proteins resulted in mutations proposing more virulent and contagious properties for this novel virus. Coronavirus penetrates the host cell via endocytosis and once infected, immune responses are triggered to fight against the pathogen. Innate immune response activates major transcription factors to secrete proinflammatory cytokines and type 1 interferon response (T1INF) to induce antiviral immunity. While adaptive immunity initiates cascade of B-cells antibody mediated and T-cells cellular mediate immunities, several mechanisms are raised by SARS-CoV-2 to evade host immune response. Consequently, a surge of proinflammatory cytokines, known as cytokine storm (CS) are released. Failure to manage CS results in several pathological complications as acute respiratory distress syndrome (ARDS). Although researches have not discovered an effective treatment against SARS-CoV-2, recent therapeutic approaches recommending the use of anti-inflammatories in combination with antivirals and some repurposed drugs for COVID-19 patients. Future medications should be designed to target essential hallmarks in the CS to improve clinical outcomes.

Keywords

COVID-19 cytokine storm immune response inflammation therapy

Background

In December 2019, the global pandemic of novel coronavirus (nCoV) disease (COVID-19) believed to be started in Wuhan, China, has subsequently dispersed around the globe¹ leading to the death of more than one million people worldwide.² Cytokine storm (CS) occurs when the immune system is exaggerated after SARS-CoV-2 infection, and it appears to be one of the common causes of mortality in the recently declared pandemic of COVID-19.³ Therapeutic approaches to manage CS might provide an avenue to decrease the COVID-19 associated morbidity and mortality rates.⁴ Moreover, drug repurposing has been approved to be effective with COVID-19 patients.⁵ The aim of this mini-review is to provide a comprehensive knowledge on COVID-19 infection and inflammatory pathways, in addition to highlight the importance of managing CS and the different treatment options associated with COVID-19 pandemic.

Pandemic challenge

As the world is facing the COVID-19 outbreak; a disease originated from the new coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), clinical data, and emerging genetics indicate a similar route to SARS-CoV and MERS (Middle East respiratory syndrome coronavirus) diseases. Merging advanced vaccine technology, high throughput genomic sequencing and open access datasets are expected to provide more knowledge about this pathogen, including the host immune response, as well as the plan for possible future therapeutics strategies.⁶

Coronaviruses infecting humans are classified into two major classes: low pathogenic and highly pathogenic CoVs. Low pathogenic human coronaviruses (HCoV) such as HCoV-229E, HCoV-NL63, HCoV-HKU, and HCoV-OC43 infect the uppers airways causing occasional mild to severe cold-like respiratory diseases. While, highly pathogenic HCoVs including SARS-CoV and MERS-CoV⁷ invade the lower respiratory tract, causing pneumonia that may result in catastrophic acute lung injury (ALI) and acute respiratory distress syndrome (ARDS).^8–10 Infection with highly pathogenic HCoVs causes wide range of clinical symptoms, where the majority of patients have phases of mild clinical illness, and only a limited number face serious ALI and ARDS.^11,12

SARS-CoV, MERS-CoV, and SARS-CoV-2 are categorized as family members of the beta-coronavirus.¹³ SARS—like coronaviruses originated in bats, while MERS-CoV have transferred from camels, make it possible that such viruses may begin to cross barriers between organisms and trigger more outbreaks in human populations.^14,15 A recent study found out a strong genetic homology between SARS-CoV-2, MERS-CoV, and SARS-CoV.¹⁶ The first recorded case of SARS-CoV infection in Guangdong Province of China was retrospectively reported in November 2002. SARS-CoV outbreak infected over 8400 confirmed cases in 37 countries over a period of 7 months, with a disease gross mortality rate of 9.6%.¹⁷ Recently in April 5, 2017, MERS-CoV infected 1936 individuals and caused death to 690 patients.¹⁸ As for February 6, 2021, World Health Organization (WHO) reported 104,956,439 confirmed cases of COVID-19, including 2,290,488 death cases.²

Viral genome

Coronaviruses are ribonucleic acid (RNA) viruses which are single-stranded, positive-sense, and enveloped nucleic acid. Genomes have a 5′ cap and 3′ poly (A) tail and are classified into non-structural protein genes and protein genes of structural and accessory type. The main structural proteins include envelope (E), matrix (M), spike (S), and nucleocapsid (N) proteins.¹⁹ Spike protein cleavage is essential for the initiation of host-virus membrane fusion and eventually cell entry. SARS-CoV-2 enters the cells when the viral structural S protein binds to the angiotensin-converting enzyme 2 (ACE2) receptor, thus virus particle enters the cell through its receptors and endosome formation.^20,21 In general, RNA viruses have intrinsically higher rates of mutation than deoxyribonucleic acid (DNA) viruses, due to the absence of proofreading ability in RNA-dependent polymerase.²² This enables them to develop at a rapid pace, particularly in combination with massive population sizes and short-term generation times. Indeed, RNA viruses have been responsible for several viral emergencies in the human communities over the past few decades,²³ such as Hepatitis C virus causing chronic hepatitis and it is an important risk factor for hepatocellular carcinoma progression, Ebola virus disease caused by Ebola virus, polio measles occurred after getting infected by poliovirus, and Orthomyxoviruses (influenza viruses) resulting in influenza disease. Other RNA viruses including Human immunodeficiency virus that causes Acquired immunodeficiency syndrome in its late stages, and Human T-cell leukemia virus (HTLV-1) that develops adult T-cell leukemia and HTLV-1 associated myelopathy/tropical spastic paraparesis.^24–27

Coronaviruses are unique RNA viruses possessing proofreading abilities in their genomes. Non-structural protein (nsp) 14 labeled as ExoN, interacts with nsp10 to perform powerful exoribonuclease activity from 3′–5′. This behavior is comparable to the DNA polymerase proofreading behavior,²⁸ as expressed in nsp14 by conserving the DEDD superfamily motif, a characteristic exonuclease activity among DNA species. If this motif is mutated in nsp14, the virus will have a 15–20 fold rise in the rate of mutation.²⁹ The improved reliability of the nsp10–nsp14 complex and the subsequent lower mutation rate seem to have granted wild-type coronaviruses to avoid error and extend their genomes by twice the fold size of the next largest genomes of RNA viruses.³⁰

SARS-CoV-2 in terms of the whole genome sequence is similar to the SARS-like bat CoVs. Most SARS-CoV-2 genomic encoded proteins share similarity with SARS-CoVs proteins along with some variations. At the protein stage, there are no substitutions of amino acids in NSP7, NSP13 envelope, matrix or accessory proteins p6 and 8b, except for NSP2, NSP3, spike protein, subdomain underpinning that is, receptor- binding domain (RBD).³¹ Another recent work suggests that NSP2 and NSP3 mutations play a role in SARS-CoV-2’s infectious capacity and differentiation process. This allows researchers to investigate the gap between SARS-CoV-2 and SARS-CoV in the host tropism and transmission, and to perform further studies on possible therapeutic targets.³² Other CoVs existed in different animal species; including birds and mammals, are classified as alpha, beta, gamma, and delta coronaviruses.^33,34

Three stages were observed in SARS-CoV-2 infection affecting patients differently. Stage I, asymptomatic phase of incubation with or without observable virus in infected patients’ blood, stage II, non-serious symptomatic cycle with detectable virus titer, and stage III, severe respiratory symptomatic stage with high viral content detected in infected patients.³⁵ Earlier it was proposed that SARS-CoV-2 would be conveyed from an asymptomatic carrier to near contacts, although this has been questioned. However, even if family members and near contacts may be compromised by the index patient during the pre-symptomatic window duration as stated, a serious concern should be addressed.³⁶ A study reported that SARS-CoV-2 had mutated in specific patients in China, although its degree of mutation is smaller than that of H7N9 avian influenza.^33,34 A community genetic study was conducted on 103 SARS-CoV-2 genomes that identified two forms of SARS-CoV-2, L type (~ 70%) and S type (~ 30%). The L strains originating from the strain S are more aggressive and infectious. The latest coronavirus needs further examination for better understanding to its epidemic nature and virulence.³⁴

The research nowadays is focused on identifying novel targets to facilitate SARS-CoV-2 recognition. One example is the heterodimer S100A8/A9, which is constituted of two Ca²⁺ binding proteins; S100A8 (MRP8) and S100A9 (MRP14).³⁷ S100A8/A9 is expressed as a Ca²⁺ sensor in the neutrophils and monocytes, and it plays a major role in moderating the inflammatory response via leukocytes recruiting and cytokines release. Such heterodimer could serve as a diagnostic biomarker in the inflammation-associated diseases, while S100A8/A9 inhibitors could be used as potential therapeutic targets in inflammatory conditions.^38,39 Another target is the high mobility group box-1 (HMGB1); a chromatin-linked protein that possess cytokine activity. HMGB1 was reported to stimulate the leukocyte adhesion, enhance the release of proinflammatory cytokines and the production of inflammatory mediators as angiogenic factors.⁴⁰ Both S100A8/A9 and HMGB1 serum levels are upregulated in COVID-19 patients, and it was observed that their elevated serum levels are associated with severity of the tissue damage and the excessive release of cytokines. Thus, they are considered indicators for the disease progression and alarming sign for the clinical risks and fatal outcomes of COVID-19.³⁸

Moreover, understanding the exact mechanism will enable identifying plethora of targets to develop antiviral drugs or repurpose the use of others.⁴¹ Researchers rely on the use of computational biology and in silico screening to identify potential targets. Four commercial drugs showed promising inhibition of main protease dimer (Mpro) and transmembrane protease serine 2 (TMPRSS2) enzymes.⁴² Human immunodeficiency virus (HIV) protease inhibitors were suggested as one of the potential therapies using in silico studies.⁴³ Furthermore, glecaprevir, paritaprevir, simeprevir, ledipasvir, glycyrrhizic acid, TMC-310911, and hesperidin showed promising effect in their free binding energies with all tested target proteins.⁴⁴

SARS-CoV-2 infection

SARS-CoV-2 invades the host cell through binding of viral spike protein to host’s ACE2 cell receptor as previously mentioned. Although ACE2 is expressed in the majority of the body organs (including lungs, oral, and nasal mucosa, nasopharynx, skin, stomach, small intestine, brain, etc.),⁴⁵ it is highly expressed on lung alveoli, secretory goblet and ciliated epithelial cells.^46,47 A recent research examined SARS-CoV-2 infected cultures, reported that the virus is targeting the ciliated cells. This result was proved by colocalization of the viral capsid S protein with acetylated tubulin, a marker for the ciliated cells.⁴⁸ Another study reported a three-fold increase in ACE2 expression in a group of epithelial cells after infection with SARS-CoV-2. Infected epithelial cells trigger the release of chemokines and stimulate host immunity to attract immune cells (e.g. neutrophils, cytotoxic T-cells, CD4 T-cells, T regulatory cells, and mast cells) at the infection site.⁴⁹ SARS-CoV-2 replication is extended from the nasopharynx to the lower respiratory tract, which may contribute to its rapid transmission.⁵⁰ Both SARS coronaviruses share some similarity in the infection pathophysiology,⁵¹ although the aggressiveness of SARS-CoV-2 is attributed to the severe inflammatory responses and the massive tissue damage. Subsequently, the host response is a key player in the disease intensity along with viral load.⁵² Once the body is exposed to SARS-CoV, the most infected immune cells are monocytes/macrophages and T cells. Similar mechanism is proposed for SARS-CoV-2 host immune interaction, as these cells were shown to have ACE2 receptors on their surfaces.^53,54 In the following section, we are going to discuss the host immune responses and different mechanisms by which SARS-CoV-2 can escape such immune response.

Host immune response

Host immune defense to viral infection is managed through immune stimulation and programmed cell death.⁵⁵ Both the adaptive and the innate immunity are joined to destroy the virus.⁵⁶

Innate immunity

The first defense line encountering any invading pathogen is the innate immunity. The main target of the innate immune response is blocking the propagation and replication of the pathogen within the body immediately after the infection.⁵⁷ It is considered as non-specific type of immunity, which recognizes conserved molecules present only in the pathogen and absent in the host, so that it can effectively fight the invading microorganism without damaging the host. These microorganism-associated features (known as pathogen-associated immunostimulants) can induce two pathways by which the innate immune response acts: phagocytosis via neutrophils and macrophages as well as systemic inflammatory responses. Both responses start immediately after the infection without any need to previous exposure history to the microorganism.⁵⁸

Immune cells can recognize the viral infection through the detection of virus derived pathogen associated molecular patterns (PAMPs) (e.g. viral RNA). Consequently, this stimulates pattern recognition receptors (PRRs) located inside or on the surfaces of immune cells resulting in immune cells stimulation. Because SARS-CoV-2 is an RNA virus, it is sensed by the immune cells through endosomal RNA PRRs; such as Toll-like receptors (TLR-3 and 7), in addition to some cytoplasmic RNA sensors; including melanoma differentiation-associated protein five (MDA5) and retinoic acid-inducible gene I (RIG-I) (Figure 1).⁵³ Activation of TLR3/7 affect major transcription factors as nuclear factor Kappa (NFκB) and interferon regulatory factor three (IRF3) causing their transportation into the nucleus^54,59 while activation of MDA5/RIG-1 triggers IRF3 activation. Thus, NFκB triggers the release of innate proinflammatory cytokines; including interleukins (IL-1/6) and tumor necrosis factor alpha (TNF-α), while IRF3 stimulates type 1 interferon (T1IFN) expression. When T1IFN is expressed, cellular response is reprogrammed to the anti-viral state, enhancing infection control, and promoting viral clearance.^60,61

Figure 1.

Activation of innate immune response. SARS-CoV-2 enters the host cell via ACE2 receptor on the cell surface. Viral infection stimulates host’s innate immunity through phagocytosis and activation of inflammatory responses. The cell detects viral infection via endosomal RNA toll-like receptors (TLR3/7) that activates NFκB to releases pro-inflammatory cytokines and IRF3 transcription factors. While viral recognition through cytoplasmic RNA sensors MDA5 and RIG-I activates only IRF3 resulting in triggering type 1 interferon.

Adaptive immunity

Adaptive immune response; which is called the specific immunity, is activated secondary to the innate immunity upon stimulation with certain pathogen. Adaptive immune cells sustain long life immunity against the invading microorganisms. The importance of such immunity is highlighted by its ability to destroy pathogens and clear the body from their toxic products.⁶² Similar to the innate immunity, the adaptive immune cells attack only the foreign particles not the host. Viral infection triggers antigen-specific immune response,⁶³ with two main players B-cells and T-cells that mediate two classes of adaptive immunity: antibody response (humoral immunity) and cell mediated immune response respectively.⁶⁴

The adaptive immune response is initiated when an antigen presenting cell (APC) activates naive T-cells by displaying the antigen, as T-cells cannot bind to free antigens in the body (Figure 2).⁶⁵ Any viral-infected cell triggered to express molecules of major histocompatibility complex (MHC) class I on its surface, can act as APC.⁶⁶ Professional APC as dendritic cells, B-cells, and macrophages can engulf the virus by endocytosis, digest its viral material and use small peptide fragments as an antigen on the MHC class II binding cleft present on the surface of APC.⁶⁶ T-cell receptor (TCR) located on the surface of naive T cell, can identify the conformational structure of peptide antigen bound to cleft of MHC on APC causing its activation. Thus, major histocompatibility complex antigen loci called human leukocyte antigen (HLA), plays essential role in the genetic susceptibility of infectious diseases.^67,68 Different haplotypes are strongly correlated to disease susceptibilities according to previous studies reported the association between specific HLA haplotypes and influenza viruses (such as H1N1).⁶⁹ Consequently, identifying alleles of MHC class I or II, in addition to HLA loci correlated with SARS-CoV-2, would provide better explanation to anti-SARS-CoV-2 immunity and facilitate development of suitable clinical management strategies.

Figure 2.

Activation of adaptive immune response. Antigen presented on the antigen presenting cell (APC) triggers naive T-cell to initiate adaptive immune response. Humoral immunity is activated through B-cells which release antibodies responsible for viral clearance. Stimulation of cell mediate immunity is achieved via activation of T-cell. CD4⁺ T-cells activates T-helper (Th) cells to release cytokines, stimulates CD8+ cells to damage the viral infected host cell, and possess stimulatory role in antibodies secretion via B-cells.

Generally, in response to pathogen infection, B-lymphocytes direct antibody mediated immune response to neutralize the virus through the release of a type of antibodies (Ab) called immunoglobulins, that recognize foreign antigen (Ag) (the virus and its toxic products). Binding of immunoglobulins to their specific antigen prevents the virus from binding to host’s cell surface receptor, in addition to marking the virus for phagocytic ingestion by the innate immune cells.⁷⁰ Moreover, cell mediate immune response is induced when stimulated T-cells initiate proliferation, differentiation, and production of cytokines.⁷¹ Activated CD4⁺ T-lymphocytes act as T-helper (Th) cells, which release proinflammatory cytokines to eliminate the virus and help other T-cells (Figure 2). They trigger B-lymphocytes to release virus-specific antibodies,⁷² and CD8⁺ T-lymphocytes to develop cytotoxic T-lymphocytes, which identify the viral infected host cell via viral antigens on the cell surface, directly attack and lyse the infected host cell.⁷⁰

However, SARS-CoV-2 stimulates destruction and death of the virus infected cells during the virus replication cycle as a part of its cytopathic mechanism.⁷³ Viral infection could also induce certain inflammatory pathway called pyroptosis, characterized by programmed cell death, normally detected with cytopathic viruses.^74,75 Pyroptosis induces the release inflammatory cytokines for example, IL-1β, in addition to other proinflammatory cytokines and inflammatory chemokines such as IL-6, interferon gamma (IFNγ), interferon gamma-induced protein 10 (IP-10), and Monocyte chemoattractant protein-1 (MCP1), which are found elevated in patients with SARS-CoV-2.^76,77 Consequently, immune cells such as monocytes and T-lymphocytes are recruited from the circulation to the site of infection.^78,79 Pulmonary attraction of such immune cells and the infiltration of the lymphocytes in the respiratory airway are the main reasons of lymphopenia and elevated ratio of neutrophil to lymphocytes in SARS-CoV-2 patients’ blood.⁵²

SARS-CoV-2 infection is correlated with dysregulation in the immune system both quantitatively and qualitatively. Analysis of COVID-19 patients peripheral blood revealed hyperactivation of lymphocytes, followed by significant reduction in total lymphocytes count. B-cells, CD4+ and CD8+ T-cells total counts were lower in patients with advanced stages when compared to mild cases.⁸⁰ CD8+ T-cells concentrations were inversely correlated with some inflammatory indicators such as IL-6, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR), while the association was positive in case of CD4+/CD8+ ratio. CD4+ T-cells concentration and total lymphocytes counts were inversely correlated with ESR, while natural killer (NK) cells were in negative association with IL-6.⁸¹ The marked lymphopenia in COVID-19 patients⁸² may be due to the excessive T-lymphocyte activation, and the increase in CD8+ and Th17 cells secondary to viral infection, resulting in massive destruction in the immune system and lymphocytes depletion.⁸³ Another potential explanation is that lymphocytes have plenty of ACE2 receptors on their surfaces, marking them for viral attachment and early destruction.⁸⁴ Qualitatively, neutrophil to lymphocyte ratio was elevated and the functions of CD8+ and NK cells were impaired in patients with SARS-CoV-2.⁸⁵ Therefore, lymphocytes might act as predictor for the infection severity, disease progression, and prognosis.⁸⁶

For better interpretation of the immune responses, some studies examined different immunological markers in SARS-CoV-2 patients’ peripheral blood. A recent research identified immune signature to differentiate between COVID-19 patients and other patients with different lower respiratory tract infection or healthy individuals. They reported that COVID-19 patient’s blood is boosted with SARS-CoV-2-specific antibodies, highly cycling T-cells, and CD8+ T-cells, which release exhaustion-associated markers, chemokine IP-10, cytokines IL-8, IL-6, and IL-10, and plasmablasts. They also reported that αβ and γδ T-cells were consumed, dendritic cells, and B-cell compartment compositions were changed.⁸⁷ Moreover, another study performed single-cell RNA sequencing for peripheral blood mononuclear cells (PBMCs) collected from COVID-19 patients and patients infected with influenza A virus. They discovered increase in X-linked inhibitor of apoptosis (XIAP)-associated factor 1 (XAF1), TNF, and FAS-induced T-cell apoptosis in SARS-CoV-2 patients. Additionally, they highlighted specific signaling pathways as STAT1 and IRF3 that were activated in COVID-19 patients. Consequently, IL-6R, IL6ST, and proinflammatory cytokines expressions were elevated. These data revealed definite immune response pathways in case of SARS-CoV-2 infection.⁸⁸

SARS-CoV-2 evasion mechanisms

In the context of SARS-CoV-2 infection, the immune response defense against the virus survival is a factor of host’s general health condition and the genetic background. Such factors can strengthen specified antiviral immunity during the viral incubation period and in non-severe stages. When the protective immunity is weakened, the virus fastens its replication and spread resulting in a tremendous destruction of the infected tissues especially lungs, kidneys and intestine owing to the increased expression of ACE2 in these organs.⁸⁹ However, during the severe infection stage, the virus protects its identity through escaping host’s immune system and inhibiting its components.^90,91 The nCoV escapes the innate immunity through suppression of TNF receptor-associated factors (TRAF 3/ 6), which is responsible for activation of both NFκB and IRF-3/7. NFκB is triggered either through TLR3/7 bonding or cytokine receptor signaling, while IRF-3/7is stimulated via RNA sensors (RIG-I and MDA-5) or TLR3/7 ligation.⁹² Highly pathogenic HCoVs generally encode viral proteins capable of disturbing RNA sensors, thus antagonizing RNA induced T1IFN synthesis.⁹³ Additionally both alphacoronaviruses and betacoronaviruses possess capability to degrade host mRNA transcripts leading to deactivation of host interferon response and suppression of T1IFN induction.⁹⁴ Other than affecting T1IFN induction, SARS-CoV-2 also deactivates phosphorylation of STAT (signal transducers and activators of transcription) family transcription factors resulting in opposing T1IFN.⁹⁵ Moreover, SARS-CoV-2 may evade the adaptive immune response by inducing TNF-mediated T-cell apoptosis.⁹⁶

Consequences of SARS-CoV-2 immunopathology

In order to extend its replication and survival period, SARS-CoV-2 has developed a mechanism to evade innate antiviral response of the human host cell. Consequently, this stimulates innate inflammatory responses via recognition of PRRs of the immune cells, resulting in a surge of proinflammatory cytokines/chemokine called cytokine storm (CS). One of the most common complications of CS is pulmonary failure and acute respiratory distress syndrome, acute cardiac injury, vascular disorders, and severe organ damage.

Cytokine storm (CS)

Once SARS-CoV-2 evaded the innate immunity and controlled cell machinery for synthesis of virion particles, at later stages the viruses destroy the cell causing cellular death, release of intracellular content, and liberation of viral molecules, thus facilitating their dissemination.⁹⁷ The enormous cytopathies and cellular debris trigger inflammasomes, leading to activation of macrophage derived eicosanoids.⁹⁸ Eicosanoids are bioactive lipid mediators (e.g. leukotrienes and prostaglandins) that fire the innate immune response and release pro-inflammatory cytokines inducing hyper-cytokinemia.^99–101 Such nonspecific immune response is known as “cytokine storm,” and is characterized by massive release of 150 inflammatory cytokines and other chemical mediators, it is marked by highly proliferating and activated T-cells, NK cells and macrophages^102,103 (Figure 3). Despite CS is the final path through which the host immune system can fight against the virus, it is also considered fatal and accounts for the higher morbidity and mortality rates of SARS-CoV-2. If left without treatment, CS would result in severe pathological complications such as sepsis, shock, huge tissue damage, that may progress to organ failure, general edema, and finally death.¹⁰³

Figure 3.

Mechanism of SARS-CoV-2 induced cytokine storm. (1) SARS-CoV-2 evades host immune response. (2) It controls cell machinery and induces synthesis of virion particles. (3) New viral particles destroy the cell causing cellular death. (4) Release of intracellular content and liberation of viral molecules. (5) Triggering of inflammasomes and hyperinflammation. (6) Stimulate host immune response. (7) Release of inflammatory cytokines.

CS hyperinflammation in COVID-19 patients is distinguishable from other types of viral induced CS, in which the increase in ferritin levels is moderate and a massive life threatening organ damage is centralized in the lungs.¹⁰⁴ Because of hyperinflammation, patients develop lymphopenia, thrombocytopenia, coagulopathy, manifested as low fibrinogen and platelet levels, and high D-dimer levels. Additionally, liver tissue damage may occur resulting in elevated levels of hepatic enzymes (aspartate aminotransferase, alanine aminotransferase, and lactate dehydrogenase), and increased ferritin levels secondary to macrophage/hepatocyte activation.^105,106 While during the early stages of inflammation, SARS-CoV-2 infected cells showed weakened interferon production facilitating the disease progression.¹⁰⁷

The release of cytokines is closely linked to Th17 responses.¹⁰⁴ Both TNF-α and IL-1β activates Th17 to increase vascular permeability. Activated Th17 cells produce different types of IL for example, IL-17, IL-21, IL-22, and granulocyte-macrophage colony-stimulating factor (GM-CSF). The proinflammatory response of IL-17 triggers the release of inflammatory cytokines such as IL-1β, IL-6, TNF-α, G-CSF,¹⁰⁸ in addition to other pro-inflammatory cytokines (e.g. IL-12, IFN-γ, and transforming growth factor beta (TGFβ)). Along with the release of chemokines for example, IL-8, IP10, keratinocyte chemoattractant (KC), macrophage inflammatory protein (MIP) 2A and MIP3A, attracting other immune cells resulting in tissue damage^108–110 The alteration in cytokines and chemokines levels is significant in severe cases of SARS-CoV-2 infected patients when compared to moderate cases. Patients with severe lethal conditions also showed increased levels of IFN (e.g. IFN-α and IFN-γ) and IFN-stimulated genes (ISGs) (such as CXCL10 and CCL-2) upon comparison with mild/moderate diseased patients or healthy individuals.^111–113 Moreover, TNF-α and IL-7 induce the release of serum amyloid, fibrinogen, mucins, and antiapoptotic proteins¹¹⁴ (Figure 3).

Subsequently, these findings suggest that the immunopathogenesis of SARS infection in humans is related to the dysregulation in inflammatory response inside our bodies. Also, the irregular and/or excessive cytokine and chemokine responses by SARS-CoV-2 infected cells are the key player in its pathogenesis. Based on these facts, targeting different key steps in the cytokine storm cascade will potentially improve outcomes in SARS-CoV-2 patients.¹¹⁵

Acute respiratory distress syndrome (ARDS)

The nonspecific innate immune response stimulation secondary to viral massive tissue damage results in acute respiratory distress syndrome. A severe respiratory failure characterized by alveolar damage, which occurs as the result of immediate diffused inflammation in the lungs and can finally leads to death.^60,78 The main symptoms of ARDS are short, rapid breathing, and cyanosis. Patients expressing such complications are referred to the intensive care units for mechanical ventilation. While in severe cases where patients are unable to breath and need life support assistance, are usually connected to extracorporeal membrane oxygenation (ECMO) machine.^89,116 Histopathological examination of pulmonary lesions in SARS patients showed nonspecific inflammatory reactions as pulmonary edema, inflammatory cell infiltration and hyaline membrane formation. Additionally, alveolar damages were recorded including alveolar epithelial cells exfoliation, widening/damage to the alveolar septa, and infiltration in the alveolar space.⁶⁰ Therefore, pathological modifications caused by inflammatory responses as degeneration (necrosis), infiltration and hyperplasia provided an explanation why some patients are manifested with severe lung injury although their viral loads were low.¹⁰⁹

Computed tomography (CT) scan on chests of SARS infected patients showed characteristic white patches filled with fluids called “ground glass.”³⁵ A recent study confirmed this through autopsies, reporting the presence of clear liquid gelatinous material filling the lungs, closely similar to lungs of wet drowning.⁷⁸ Although the composition of such clear liquid jelly has not been yet identified, previous researches explained the strong correlation between hyaluronan (HA) and ARDS.¹¹⁷ HA is a glycosaminoglycan ingredient present at high concentrations in the extracellular matrix of the lungs and it is capable of absorbing amounts of water 1000 times of its molecular weight. The production and organization of HA is disturbed during SARS infection, moreover the elevated levels of proinflammatory cytokines during cytokine storm stimulate HA-synthase-2 (HAS2) in lung alveolar epithelial cells, CD31⁺ endothelium and fibroblasts.¹¹⁸ Subsequently, the use of medical grade hyaluronidase could decrease the accumulation of HA in the lungs, thus reduce one of the pulmonary complications in SARS-CoV-2 patients.⁸⁹

Coagulation and vascular disorders

One of the prevalent characteristics of CS is the cardiovascular disorder, in which the patients are manifested with disseminated intravascular coagulation, capillary leakage, and reduction in blood pressure.¹¹⁹ Generally, the immune-mediated pathways associated with systemic infections may result in cytolytic events such as endothelial cell death. Once they are exposed to the circulating cytokines, body systems maintain their silence and develop a conserved hemostatic response. This hemostatic mechanism involves platelets recruitment and fibrin deposition to achieve blood coagulation and reduce blood loss.¹²⁰ The surge of systemic cytokines is usually accompanied by decrease in platelet numbers expressing their consumption. Although these events are considered host-protective mechanisms, prolonged systemic infection may result in extensive thrombus formation followed by vascular closure, disseminated intravascular coagulation, tissue damage, and finally host’s death. The vascular endothelial cells of the lungs and kidneys were found to be the most vulnerable areas to the complement mediated injury, and the highly affected endothelial dysfunctions.¹²¹

Infection with COVID-19 increases the risk of hypercoagulation and the incidence rates of arterial and venous thrombosis, especially in younger patients.¹²² Several coagulation disorders were manifested in COVID-19 patients, such as ischemic stroke in large vessels that was reported in patients with mild symptoms or even in asymptomatic patients.¹²³ Also, advanced stages of COVID-19 infection were accompanied by higher proportions of acute venous thromboembolism.¹²⁴ A recent study reported that 25% of patients admitted to the intensive care unit (ICU) who haven’t receive any anticoagulant prophylactic therapy, developed deep vein thrombosis in the lower extremities, while 40% of the patients experienced death.¹²⁵ The most widespread thrombotic complication following COVID-19 infection is the pulmonary embolism, which may result in acute right ventricular failure.¹²⁶ However, some patients may suffer also form ischemic stroke, myocardial infarction, deep vein thrombosis, and systemic arterial embolism.¹²⁷ Despite no previous history of heart failure, 25% of COVID-19 hospitalized patients, and 33% of patients at the ICU were diagnosed with heart failure.^128,129 A possible explanation could be attributed to SARS-CoV-2 direct effect or due to systemic inflammation that affects the heart. Consequently, severe acute myocarditis, and cardiogenic shock may occur, resulting in multi-organ damage and finally death.^130,131

Suggested therapies and treatments

The urge for the development of an effective therapy against COVID-19 infection is focused on understanding coronavirus pharmacological and toxicological mechanisms in human body.⁵ Drug repurposing is one of the widely utilized approaches, to redesign the use of previously approved drugs in COVID-19 treatment, based on information of their mechanism of actions.^132–136 An example of these repurposed drugs (summarized in Table 1) is relying on the mechanism of viral internalization by endocytosis,¹³⁷ suggesting repurposing of previously approved drug for blocking SARS-CoV-2 endocytosis. Another examples include the use of antidepressants such as fluvoxamine, sertraline, and imipramine,^137–140 and antifungals such as nystatin, and itraconazole as promising options in COVID-19 treatment. In addition to other classes of medications for example, antihistamines such as promethazine and terfenadine,^{137,140–142} diuretics such as amiloride, microtubule formation inhibitor such as vinblastine, antihelminthic such as flubendazole, and beta-methyl cyclodextrin as a bioavailability enhancer were all found to have high efficacy in improving therapeutic outcomes in COVID-19 patients.^137,140

Table 1.

Different ongoing clinical trials were conducted for the approval of COVID-19 treatment.

Class	Drugs	Mechanism of action	References
Selected Repurposed Drugs	✔ Chloroquine and Hydroxychloroquine	Antimalarials—inhibit SARS-CoV-2 activity and reduce its replication	^{146, 170–180}
	✔ Lopinavir/Ritonavir and Other Antiretrovirals	HIV protease inhibitors—inhibit SARS-CoV-2 protease	^{146, 180–184}
	✔ Ribavirin	Guanine analog—inhibits SARS-CoV-2 replication	^{143, 180, 185–187}
	✔ Camostat mesylate and Nafamostat mesylate	Inhibitors of TMPRSS2—block SARS-CoV-2 spread and pathogenesis	^{146,171,177,188–192}
	✔ Chlorpromazine	Antipsychotic—blocks endocytosis mechanism of coronavirus entry into the host cell	^{137, 193–195}
	✔ Fluvoxamine, Setraline, Imipramine	Antidepressants—reduce overwhelming inflammatory immune response	^137–140
	✔ Nystatin, Itraconazole	Antifungals—block endocytosis mechanism of coronavirus entry into the host cell	^{137, 140, 193}
	✔ Promethazine, Terfenadine	Antihistaminics—block endocytosis mechanism of coronavirus entry into the host cell	^{137, 140–142}
	✔ Amiloride	Diuretic—blocks endocytosis mechanism of coronavirus entry into the host cell	¹³⁷
	✔ Vinblastine	Inhibitor of microtubule formation—blocks endocytosis mechanism of coronavirus entry into the host cell	^{137, 140}
	✔ Flubendazole	Antihelminthic—blocks endocytosis mechanism of coronavirus entry into the host cell	^{137, 140}
	✔ Beta-methyl cyclodextrin	Bioavailability enhancer—blocks endocytosis mechanism of coronavirus entry into the host cell	^{137, 196, 197}
	✔ Sildenafil	PDE5 inhibitor—Counters the inflammatory cascade and thromboembolic episodes	^198–202
	✔ Cimetidine* Famotidine	Inhibit pathological blood clotting and reduce inflammation	¹⁹⁹
	✔ Dipyridamole	Suppresses severe acute respiratory syndrome	^{199, 203}
	✔ Fenofibrate* Bezafibrate	Address the hypercoagulability in COVID-19 patients	¹⁹⁹
Review of SelectInvestigationalDrugs	✔ Remdesivir	Antiviral—inhibits SARS-CoV-2 infection	^{146, 171, 177, 204–207}
Review of SelectInvestigationalDrugs	✔ Favipiravir	Antiviral—inhibits SARS-CoV-2 replication	^{146, 171, 192, 208–210}
Adjunctive Therapies	✔ Corticosteroids	Inhibitor of exaggerated T-cells, macrophages and inflammatory cytokines	^{64, 172, 211–214}
	✔ Anticytokine or Immunomodulatory Agents	Control viral replication and prevent multiple organ damage	^212–216
	✔ Immunoglobulin Therapy	Triggers immunity, immunomodulatory and anti-inflammatory effects, and improves treatment efficacy.	^{150, 166, 172, 211, 214, 217}
	✔ Low molecular weight heparin or it’s alternatives	Prophylactic against thrombotic complications	^218–221

Despite the ongoing clinical trials, no therapy was found successful against SARS-CoV-2 infection up to date.^143,144 There is no strong evidence that a potential or prophylactic therapy is available to enhance outcomes in patients with suspected or confirmed COVID-19. However, the rapidly growing awareness about SARS-CoV-2 virology may provide multiple potential targets for medicines. Remdesivir is the most effective treatment discovered so far as it has proven a potent effect in vitro, and currently it is only being evaluated in ongoing randomized trials, yet it has been licensed recently by the United States Food and Drug Administration (FDA).¹⁴⁵ Oseltamivir has not been proven to be effective and officially corticosteroids are not approved.¹⁴³ Current research suggests the use of TMPRSS2 inhibitors such as camostat mesylate and nafamostat mesylate, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, inhibitors of replication, membrane fusion and assembly of SARS-CoV-2 such as remdesivir and umnifenovir, and 3-Chymotrypsin like protease (3CL^pro) inhibitors in COVID-19 patients.¹⁴⁶ Currently various clinical trials are conducted to test the potential treatments of COVID-19, which are summarized in Table 1.^143,146 However, the new treatment guidelines for COVID-19, according to the National Institutes of Health (NIH), are focused on the following treatment options:

Antithrombotic therapy

Infection with COVID-19 has been associated with inflammation and a prothrombotic state.¹⁴⁵ Although the occurrence of thrombotic complications is unclear, some reports have been seen of COVID-19 related thromboembolic disease in patients admitted to the ICU.¹⁴⁷ Several clinical trials are being conducted nowadays, some are recruiting subjects as in St. Michael’s Hospital, Geneva Hospitals, and NYU Langone Health for example, (“Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care—Full Text View—ClinicalTrials.gov,” 2020; “Preventing COVID-19 Complications With Low- and High-dose Anticoagulation—Full Text View—ClinicalTrials.gov,” 2020; “A Randomized Trial of Anticoagulation Strategies in COVID-19—Full Text View—ClinicalTrials.gov,” 2020). Other trials are still in progress as conducted by (“Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19—Full Text View—ClinicalTrials.gov,” 2020). The American Society of Hematology suggested the use of low molecular weight heparin or any alternative as a prophylactic therapy against thrombosis for all COVD-19 hospitalized patients, after comparing the coagulation complications to the high risk of bleeding in some cases.¹⁴⁸

Antiviral drugs

Based on the recommendations of the National Institutes of Health,¹⁴⁵ Remdesivir is available as FDA (food and drug administration) emergency drug for treatment of COVID-19 patients with severe cases. On the other hand, Chloroquine/Hydroxychloroquine are used with some restriction (only low doses) to avoid toxicities.

Immune-based therapy

According to NIH guidelines¹⁴⁹ summarized in Table 2, no reliable data is available to use the convalescent plasma or intravenous immune globulins of cured COVID-19 in the treatment. Although some research studies were conducted on patients showed a promising effect, yet the efficacy and safety of convalescent plasma need further investigation.^150–152 Cytokine targeting therapies (Table 2) are based on blocking IL-1, IL-6, and TNF-α, as these molecules are highly upregulated in patients with COVID-19. Although different clinical trials are ongoing to assess the effectiveness of these therapies. One example of IL-1 receptor antagonist is anakinra, which showed a promising effect in blocking the biologic activity of IL-1.^153–156 Examples of IL-6 inhibitors are tocilizumab, siltuximab, and sarliumab, which also had a potential therapeutic effect in COVID-19 patients.^157–159 Some ongoing trials are being tested for the effectiveness of TNF-α blockers.¹⁶⁰ Other immune based therapies used for treatment of SARS-CoV-2 infected patients are Janus kinase inhibitors such as barcitinib.¹⁶¹ Furthermore, mesenchymal stem cells^162,163 possessed potent immunomodulatory activities, intravenous immunoglobulin and convalescent plasma therapies were other therapeutic options shown effectiveness in COVID-19 patients.^164–167

Table 2.

Immune-based therapies used in ongoing clinical trials for treatment of COVID-19.

Drug name	FDA-approved indications	Rationale for use in COVID-19	Clinical data for COVID-19
Blood products
1. COVID-19 Convalescent Plasma and SARS-CoV-2 Immune Globulins	Not approved by the FDA	Plasma collected from treated COVID-19 people contains antibodies to SARS-COV-2. Similarly, the immunoglobulin is a concentrated plasma-derived antibody preparation from people recovered from COVID-19. Both have been found to play a role in modifying the inflammatory response and suppressing the virus.	Only small studies were conducted on the use of convalescent plasma. No clinical data is found on immune globulin or hyperimmune globulin
2. Non-SARS-CoV-2 Specific Intravenous Immune Globulin	Used to treat different immune, inflammation, bacterial and viral diseases	Plasma blood donors contain human immunoglobulin that contains antibodies with a broad spectrum against pathogens	Ongoing clinical trials are being tested for those infected with COVID-19, however nothing is confirmed
Interferons
1. Interferon-Alfa	Used in treatment of different cancer disorders and hepatitis	Antiviral and has immunomodulatory activities	No clinical data for COVID-19
2. Interferon-Beta	Approved in multiple sclerosis	Antiviral and has immunomodulatory activities	No clinical data for COVID-19
Interleukin-1 Inhibitor
1. Anakinra	Rheumatoid arthritis	Inhibits IL-1 and binds to its type 1 receptor	No clinical data for COVID-19
Interleukin-6 inhibitors
1. Sarilumab.2. Tocilizumab	Rheumatoid arthritis	Humanized clonal antibody. IL-6 receptor antagonist	Ongoing clinical trials, nothing yet confirmed
3. Siltuximab	Multicentric Castleman disease	Human -mouse chimeric monoclonal antibody. IL-6 antagonist	Ongoing clinical trials, nothing yet confirmed
Janus Kinase Inhibitor
1. Baricitinib	Rheumatoid arthritis	JAK inhibitor Inhibits AAK1	No clinical data for COVID-19

Complementary and alternative medicine

Recently scientists are proposing the use of complementary and alternative medications as an adjunct therapy for COVID-19. Many countries relied on the use of natural preparations such as amla, tulsi, coronil, and giloy.¹⁶⁸ While some studies addressed the use of vitamin C, zinc, and immunomodulatory supplements to increase patient’s quality of life and reduce the complications.¹⁶⁹

Conclusion and future prespectives

The outbreak of SARS-CoV-2 has raised an alert on the importance of studying viral transmission across the species. The virulence of SARS-CoV-2 relies on its ability to infect the lower respiratory tract which may progress to pneumonia and severe lung injury. Binding of viral S protein to ACE2 receptor, expressed on the cellular surfaces of multiple organs, results in severe organ damage in its advanced stages. The interaction between SRAS-CoV-2 and the host antiviral immune response is essential for the pathogenicity. The novelty of SARS-CoV-2 to human beings resulted in absence of acquired immunity against it and to more complex and ambiguous perspective to the host immune responses. Whereas, with immunocompromised patients and in severe cases, SARS-CoV-2 possesses an ability to evade the host immune responses followed by several inflammatory complications progressing to CS. The severity of CS is a factor of patient’s age, genetic variability and the presence of other pathological conditions or comorbidities.

COVID-19 disease affected all walks of life globally.^222–227 Currently, there has not been a single approved treatment proved to be effective against SARS-CoV-2 infection. However, according to the World Health Organization, social distance, and hand washing are the main protective measures against COVID-19. Improving the ventilation rate, avoiding air recirculation, reducing the number of people and the direct contact with them will aid in reducing the disease transmission. Most available treatment protocols depend on the use of combination therapies including antiviral, anti-inflammatory, and immunomodulatory based on the available limited clinical trials and comparative analyzes with SARS-CoV. It is recommended to maintain the balance between the use of anti-inflammatories and sustaining the effective antiviral immune response. Targeting specific key steps in the cytokine storm pathway could provide a novel therapeutic option to decrease patients’ suffering and improve treatment outcomes. Moreover, studying MHC class I and II alleles in SARS-CoV-2 and determining HLA loci would provide an insight for development of anti-SARS-CoV-2 vaccines and designing effective clinical management plan against COVID-19.

Footnotes

Acknowledgements

The authors want to thank their respective institutions for their continued support. The language and technical editing support provided by The Editing Refinery, MD, USA is highly acknowledged.

Authors’ contributions

AD and NY performed literature research, gathered, and analyzed information, and generated short preliminary write-ups. MS, MME, and MWQ conceptual work, framework, draft write-up, critical reading, and editing. All authors read and approved the final manuscript.

Availability of data and materials

This is a review article. All data generated or analyzed during this study are included in this published article.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iDs

Areeg M Dabbish

Musthafa M Essa

M Walid Qoronfleh

References

Zhu

Zhang

Wang

, et al. (2020) A novel coronavirus from patients with pneumonia in China, 2019. The New England Journal of Medicine 382: 727–733.

WHO. (2020) WHO Coronavirus Disease (COVID-19) Dashboard | WHO Coronavirus Disease (COVID-19) Dashboard.

Coperchini

Chiovato

Croce

, et al. (2020) The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine and Growth Factor Reviews 53: 25–32.

Ragab

Salah Eldin

Taeimah

, et al. (2020) The COVID-19 Cytokine Storm; What We Know So Far. Frontiers in Immunology 11: 1446.

Fajgenbaum

Khor

Gorzewski

, et al. (2020) Treatments administered to the first 9152 reported cases of COVID-19: a systematic review. Infectious Diseases and Therapy 9: 435–449.

Prompetchara

Ketloy

Palaga

. Allergy and immunology immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. DOI: 10.12932/AP-200220-0772.

Heugel

Martin

Kuypers

, et al. (2007) Coronavirus-associated pneumonia in previously healthy children. Journal of Pediatric Infectious Diseases 26: 753–755.

Zaki

van Boheemen

Bestebroer

, et al. (2012) Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. The New England Journal of Medicine 367: 1814–1820.

van Boheemen

de Graaf

Lauber

, et al. (2012) Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio. Epub ahead of print. DOI: 10.1128/mBio.00473-12.

10.

Mostafa

Gamal

Wafiq

(2021) The impact of COVID 19 on air pollution levels and other environmental indicators – A case study of Egypt. Journal of Environmental Management 277: 111496.

11.

Weiss

Navas-Martin

(2005) Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiology and Molecular Biology Reviews 69: 635–664.

12.

Assiri

Al-Tawfiq

Al-Rabeeah

, et al. (2013) Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: A descriptive study. The Lancet Infectious Diseases 13: 752–761.

13.

Chen

(2020) Pathogenicity and transmissibility of 2019-nCoV—A quick overview and comparison with other emerging viruses. microbes & Infections 22: 69–71.

14.

NIH. What’s new and Coronavirus Disease COVID-19.

15.

Alagaili

Briese

Mishra

, et al. (2014) Middle east respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia. MBio. Epub ahead of print February. DOI: 10.1128/mBio.00884-14.

16.

Ren

Wang

, et al. (2020) Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chinese Medical Journal (Engl). Epub ahead of print May. DOI: 10.1097/CM9.0000000000000722.

17.

Perlman

Netland

(2009) Coronaviruses post-SARS: Update on replication and pathogenesis. Nature Reviews Microbiology 7: 439–450.

18.

Senga

Arabi

Fowler

(2017) Clinical spectrum of the Middle East respiratory syndrome coronavirus (MERS-CoV). Journal of Infections Public Health 10: 191–194.

19.

Graham

Donaldson

Baric

(2013). A decade after SARS: Strategies for controlling emerging coronaviruses. Nature Reviews Microbiology 11: 836–848.

20.

Domingo

Mur

Pomar

, et al. (2020) The four horsemen of a viral Apocalypse: The pathogenesis of SARS-CoV-2 infection (COVID-19). EBioMedicine 58: 102887.

21.

Zheng

Cao

(2020) ACE gene polymorphism and severe lung injury in patients with COVID-19. American Journal of Pathology. Epub ahead of print July. DOI: 10.1016/j.ajpath.2020.07.009.

22.

Steinhauer

Domingo

Holland

(1992). Lack of evidence for proofreading mechanisms associated with an RNA virus polymerase. Genes 122: 281–288.

23.

Woolhouse

MEJ

Gowtage-Sequeria

(2005). Host range and emerging and reemerging pathogens. Emerging Microbes & Infections 11: 1842–1847.

24.

Poltronieri

Sun

Mallardo

(2015) RNA viruses: RNA roles in pathogenesis, coreplication and viral load. Current Genomics 16: 327–335.

25.

Carrasco-Hernandez

Jácome

Vidal

, et al. (2017) Are RNA viruses candidate agents for the next global pandemic? A review. ILAR Journal 58: 343–358.

26.

RNA Viruses - an overview and ScienceDirect Topics, https://www.sciencedirect.com/topics/immunology-and-microbiology/rna-viruses (accessed 7 February 2021).

27.

Shantha

Hayek

Crozier

, et al. (2018) Development of a screening eye clinic for Ebola virus disease survivors: Lessons learned and rapid implementation at ELWA Hospital in Monrovia, Liberia 2015. PLoS Neglected Tropical Diseases. Epub ahead of print 1 March 2018. DOI: 10.1371/journal.pntd.0007209.

28.

Minskaia

Hertzig

Gorbalenya

, et al. (2006) Discovery of an RNA virus 3′→5′ exoribonuclease that is critically involved in coronavirus RNA synthesis. Proceeding of the National Academy of Sciences of the United States of America 103: 5108–5113.

29.

Eckerle

Sperry

, et al. (2007) High fidelity of murine hepatitis virus replication is decreased in nsp14 exoribonuclease mutants. Journal of Virology 81: 12135–12144.

30.

Lauber

Goeman

de Parquet

, et al. (2013) The footprint of genome architecture in the largest genome expansion in RNA viruses. PLoS Pathogens. Epub ahead of print July 2013. DOI: 10.1371/journal.ppat.1003500.

31.

Peng

Huang

, et al. (2020) Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host and Microbe 27: 325–328.

32.

Angeletti

Benvenuto

Bianchi

, et al. (2020) COVID-2019: The role of the nsp2 and nsp3 in its pathogenesis. Journal of Medical Virology 92: 584–588.

33.

Zou

Bai

, et al. (2015) Poultry farms as a source of avian influenza A (H7N9) virus reassortment and human infection. Scintific Report. Epub ahead of print 2015. DOI: 10.1038/srep07630.

34.

Guo

Cao

Hong

, et al. (2020) The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak- A n update on the status. Military Medical Research. Epub ahead of print March 2020. DOI: 10.1186/s40779-020-00240-0.

35.

Wang

, et al. (2020) Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. Journal of the American Medical Association 323: 1061–1069.

36.

Bai

Yao

Wei

, et al. (2020) Presumed Asymptomatic Carrier Transmission of COVID-19. Journal of the American Medical Association 323: 1406–1407.

37.

Wang

Song

Wang

, et al. (2018) S100A8/A9 in inflammation. Frontiers in Immunology 9: 1298.

38.

Chen

Long

, et al. (2020) Elevated serum levels of S100A8/A9 and HMGB1 at hospital admission are correlated with inferior clinical outcomes in COVID-19 patients. Cellular and Molecular Immunology 17: 992–994.

39.

Guo

Zhao

, et al. (2021) Induction of alarmin S100A8/A9 mediates activation of aberrant neutrophils in the pathogenesis of COVID-19. Cell Host and Microbe. Epub ahead of print 26 December 2021. DOI: 10.1016/j.chom.2020.12.016.

40.

Street

(2020) HMGB1: a possible crucial therapeutic target for COVID-19? Hormone Research in Paediatrics 93: 73–75.

41.

Riva

Yuan

Yin

, et al. (2020) Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature 586: 113–119.

42.

Elmezayen

Al-Obaidi

Şahin

, et al. (2020) Drug repurposing for coronavirus (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes. Journal of Biomolecular Structure and Dynamics 1–13.

43.

Shah

Modi

Sagar

(2020) In silico studies on therapeutic agents for COVID-19: Drug repurposing approach. Life Science 252: 117652.

44.

Mahdian

Ebrahim-Habibi

Zarrabi

(2020) Drug repurposing using computational methods to identify therapeutic options for COVID-19. Journal of Diabetes and Metabolic Disorders 19: 1–9.

45.

Hamming

Timens

Bulthuis

, et al. (2004) Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. Journal of Pathology 203: 631–637.

46.

Sims

Baric

Yount

, et al. (2005) Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia: role of ciliated cells in viral spread in the conducting airways of the lungs. Journal of Virology 79: 15511–15524.

47.

Sungnak

Huang

Bécavin

, et al. (2020) SARS-CoV-2 entry genes are most highly expressed in nasal goblet and ciliated cells within human airways. Nature Medicine 26: 681–687.

48.

Mulay

Konda

Garcia

, et al. (2020) SARS-CoV-2 infection of primary human lung epithelium for COVID-19 modeling and drug discovery. bioRxiv. Epub ahead of print 2020. DOI: 10.1101/2020.06.29.174623.

49.

Chua

Lukassen

Trump

, et al. (2020) COVID-19 severity correlates with airway epithelium–immune cell interactions identified by single-cell analysis. Nature Biotechnology 38: 970–979.

50.

Perlman

(2020) Lessons for COVID-19 immunity from other coronavirus infections. Immunity. Epub ahead of print 2020. DOI: 10.1016/j.immuni.2020.07.005.

51.

Zhao

, et al. (2020) Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet 395: 565–574.

52.

Tay

Poh

Rénia

, et al. (2020) The trinity of COVID-19: immunity, inflammation and intervention. Nature Reviews Immunology 20: 363–374.

53.

Felsenstein

Herbert

McNamara

, et al. (2020) COVID-19: Immunology and treatment options. Clinical Immunology 215: 108448.

54.

Prompetchara

Ketloy

Palaga

(2020) Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pacific Journal of Allergy and Immunology 38: 1–9.

55.

Zinkernagel

(2004) On immunity against infections and vaccines: Credo 2004. Scandinavian Journal of Immunology 60: 9–13.

56.

Savarin

Bergmann

(2018) Fine Tuning the Cytokine Storm by IFN and IL-10 Following Neurotropic Coronavirus Encephalomyelitis. Frontiers in Immunology 9: 3022.

57.

Riera Romo

Pérez-Martínez

Castillo Ferrer

(2016) Innate immunity in vertebrates: An overview. Immunology 148: 125–139.

58.

Alberts

Johnson

Lewis

, et al. Innate immunity, https://www.ncbi.nlm.nih.gov/books/NBK26846/ (2002, accessed 9 August 2020).

59.

De Wit

Van Doremalen

Falzarano

, et al. (2016) SARS and MERS: Recent insights into emerging coronaviruses. Nature Reviews Microbiology 14: 523–534.

60.

Fan

Lai

, et al. (2020) Coronavirus infections and immune responses. Journal of Medical Virology 92: 424–432.

61.

Lazear

Schoggins

Diamond

(2019) Shared and Distinct Functions of Type I and Type III Interferons. Immunity 50: 907–923.

62.

Vardhana

Wolchok

(2020) The many faces of the anti-COVID immune response. The Journal of Experimental Medicine 217. Epub ahead of print June 2020. DOI: 10.1084/jem.20200678.

63.

Nathanson

. Viral Pathogenesis and Immunity - Neal Nathanson - Google Books.

64.

Pachter; JSHE de V; Zsuzsa F. The Adaptive Immune System - Molecular Biology of the Cell. Garland Science, NCBI Bookshelf.

65.

Pachter

De Vries

Fabry

. The Blood-Brain Barrier and Its Role in Immune Privilege in the Central Nervous System. Oxford, UK: Oxford Academic.

66.

Carson

Doose

Melchior

, et al. (2006) CNS immune privilege: Hiding in plain sight. Immunological Reviews 213: 48–65.

67.

Blackwell

Jamieson

Burgner

(2009) HLA and infectious diseases. Clinical Microbiology Reviews 22: 370–385.

68.

Matzaraki

Kumar

Wijmenga

, et al. (2017) The MHC locus and genetic susceptibility to autoimmune and infectious diseases. Genome Biology; 18. Epub ahead of print April 2017. DOI: 10.1186/s13059-017-1207-1.

69.

Dutta

Medhi

, et al. (2018) Polymorphism of HLA class I and class II alleles in influenza A(H1N1)pdm09 virus infected population of Assam, Northeast India. Joural of Medical Virology 90: 854–860.

70.

CKF

(2010) Host immune responses to SARS coronavirus in humans. In: Lal SK (ed) Molecular Biology of the SARS-Coronavirus. Berlin, Heidelberg: Springer, pp. 259–278.

71.

Libbey

Fujinami

(2014) Adaptive immune response to viral infections in the central nervous system. In: Alex

John

(eds) Handbook of Clinical Neurology. Elsevier B.V., pp. 225–247.

72.

Yan

, et al. (2008) T Cell Responses to Whole SARS Coronavirus in Humans. Journal of Immunology 181: 5490–5500.

73.

Park

Kwon

Choi

, et al. (2020) Virus isolation from the first patient with SARS-CoV-2 in Korea. Journal of Korean Medical Science 35. Epub ahead of print February 2020. DOI: 10.3346/jkms.2020.35.e84.

74.

Zhang

Gao

Qiao

, et al. (2020) Inflammatory response cells during acute respiratory distress syndrome in patients with coronavirus disease 2019 (COVID-19). Annals of Internal Medicine. Epub ahead of print April 2020. DOI: 10.7326/L20-0227.

75.

Fink

Cookson

(2005) Apoptosis, pyroptosis, and necrosis: Mechanistic description of dead and dying eukaryotic cells. Infection and Immunity 73: 1907–1916.

76.

Zhang

Zhou

Qiu

, et al. (2020) Clinical characteristics of 82 death cases with COVID-19. medRxiv 2020.02.26.20028191.

77.

Huang

Wang

, et al. (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 395: 497–506.

78.

Shi

Wang

, et al. (2020) Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respiratory Medicine 8: 420–422.

79.

Tian

Niu

, et al. (2020) Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. Journal of Thoracic Oncology 15: 700–704.

80.

Qin

Zhou

, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clinical Infectious Diseases 71: 762–768.

81.

Wang

Nie

Wang

, et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. The Journal of Infectious Diseases 221: 1762–1769.

82.

Lin

Cao

, et al. (2020) Hypothesis for potential pathogenesis of SARS-CoV-2 infection–a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect 9: 727–732.

83.

Diao

Wang

Tan

, et al. (2020) Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Frontiers in Immunology 11: 827.

84.

Zhong

Deng

, et al. (2020) High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. International Journal of Oral Science 12: 1–5.

85.

Zheng

Gao

Wang

, et al. (2020) Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cellular and Molecular Immunology 17: 533–535.

86.

Ghayda

Lee

, et al. (2020) Correlations of clinical and laboratory characteristics of COVID-19: a systematic review and meta-analysis. International Journal of Environmental Health Research 17: 5026.

87.

Laing

Lorenc

del Molino del Barrio

, et al. (2020) A dynamic COVID-19 immune signature includes associations with poor prognosis. Nature Medicine 26: 1623–1635.

88.

Zhu

Yang

Zhao

, et al. (2020) Single-cell sequencing of peripheral mononuclear cells reveals distinct immune response landscapes of COVID-19 and influenza patients. Immunity 53: 685–696.e3.

89.

Shi

Wang

Shao

, et al. (2020) COVID-19 infection: the perspectives on immune responses. Cell Death and Differentiation 27: 1451–1454.

90.

Kindler

Thiel

Weber

(2016) Interaction of SARS and MERS Coronaviruses with the Antiviral Interferon Response. In: Mettenleiter

Kielian

Roossinck

(eds) Advances in Virus Research. Academic Press Inc., pp. 219–243.

91.

Channappanavar

Perlman

(2017) Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Seminars in Immunopathology 39: 529–539.

92.

Sallenave

Guillot

(2020) Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets? Frontiers in Immunology 11: 1229.

93.

Siu

K-L

Yeung

Kok

K-H

, et al. (2014) Middle east respiratory syndrome coronavirus 4a protein is a double-stranded RNA-binding protein that suppresses PACT-induced activation of RIG-I and MDA5 in the innate antiviral response. Journal of Virology 88: 4866–4876.

94.

Tohya

Narayanan

Kamitani

, et al. (2009) Suppression of Host Gene Expression by nsp1 Proteins of Group 2 Bat Coronaviruses. Journal of Virology 83: 5282–5288.

95.

Zhang

Qiao

, et al. (2020) Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19. International Immunopharmacology 86: 106749.

96.

Yuksel

Karadogan

Gurkan

, et al. (2020) Unclear issues regarding COVID-19. Eurasian Journal of Medicine 52: 191–196.

97.

Lagniton

PNP

, et al. (2020) COVID-19: what has been learned and to be learned about the novel coronavirus disease. International Journal of Biological Sciences 16: 1753–1766.

98.

Panigrahy

Gilligan

Huang

, et al. (2020) Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19? Cancer Metastasis Reviews 39: 337–340.

99.

Dennis

Norris

(2015) Eicosanoid storm in infection and inflammation. Nature Reviews Immunology 15: 511–523.

100.

Gartung

Yang

Sukhatme

, et al. (2019) Suppression of chemotherapy-induced cytokine/lipid mediator surge and ovarian cancer by a dual COX-2/sEH inhibitor. Proceedings of the National Academy of Sciences of the United States of America 116: 1698–1703.

101.

Serhan

(2014) Pro-resolving lipid mediators are leads for resolution physiology. Nature 510: 92–101.

102.

Zhang

Liu

, et al. (2020) Existing bitter medicines for fighting 2019-nCoV-associated infectious diseases. FASEB Journal 34: 6008–6016.

103.

Wong

Viswanathan

Wang

, et al. (2017) Current and future developments in the treatment of virus-induced hypercytokinemia. Future Medicinal Chemistry 9: 169–178.

104.

Jesenak

Brndiarova

Urbancikova

, et al. (2020) Immune parameters and COVID-19 infection – associations with clinical severity and disease prognosis. Frontiers in Cellular and Infection Microbiology 10: 364.

105.

Henderson

Canna

Schulert

, et al. (2020) On the Alert for Cytokine Storm: Immunopathology in COVID-19. Arthritis and Rheumatology 72: 1059–1063.

106.

Chen

Cai

, et al. (2020) Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Internal Medicine 180: 934–943.

107.

Chu

Fuk-Woo Chan

Wang

, et al. (2020) Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19. Clinical Infectious Diseases 71: 1400–1409.

108.

Yang

(2020) TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib. Journal of Microbiology, Immunology, and Infection 53: 368.

109.

Chien

Hsueh

Cheng

, et al. (2006) Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome. Respirology 11: 715–722.

110.

Wong

Lam

CWK

AKL

, et al. (2004) Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Journal of Clinical and Experimental Immunology 136: 95–103.

111.

Cameron

Bermejo-Martin

Danesh

, et al. (2008) Human immunopathogenesis of severe acute respiratory syndrome (SARS). Virus Research 133: 13–19.

112.

Huang

Theron

, et al. (2005) An interferon-γ-related cytokine storm in SARS patients. Journal of Medical Virology 75: 185–194.

113.

Cameron

Ran

, et al. (2007) Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. Journal of Virology 81: 8692–8706.

114.

Allegra

Di Gioacchino

Tonacci

, et al. (2020) Immunopathology of SARS-CoV-2 Infection: Immune Cells and Mediators, Prognostic Factors, and Immune-Therapeutic Implications. International Journal of Molecular Sciences 21: 4782.

115.

Zhang

Wang

, et al. (2020) COVID-19: Melatonin as a potential adjuvant treatment. Life Sciences 250: 117583.

116.

Maclaren

Fisher

Brodie

(2020) Preparing for the most critically Ill patients with COVID-19: the potential role of extracorporeal membrane oxygenation. JAMA - Journal of the American Medical Association 323: 1245–1246.

117.

Esposito

Bhatraju

Stapleton

, et al. (2017) Hyaluronic acid is associated with organ dysfunction in acute respiratory distress syndrome. Critical Care; 21. Epub ahead of print December 2017. DOI: 10.1186/s13054-017-1895-7.

118.

Bell

Brand

Morgan

, et al. (2019) Defective lung function following influenza virus is due to prolonged, reversible hyaluronan synthesis. Matrix Biology 80: 14–28.

119.

Tang

Liu

Zhang

, et al. (2020) Cytokine Storm in COVID-19: The current evidence and treatment strategies. Frontiers in Immunology 11: 1708.

120.

Mangalmurti

Hunter

(2020) Cytokine storms: understanding COVID-19. Immunity 53: 19–25.

121.

Bhaskar

Sinha

Banach

, et al. (2020) Cytokine storm in COVID-19—immunopathological mechanisms, clinical considerations, and therapeutic approaches: The REPROGRAM consortium position paper. Frontiers in Immunology 11: 1648.

122.

Bikdeli

Madhavan

M V.

Jimenez

, et al. (2020) COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. Journal of the American College of Cardiology 75: 2950–2973.

123.

Oxley

Mocco

Majidi

, et al. (2020) Large-vessel stroke as a presenting feature of Covid-19 in the young. The New England Journal of Medicine 382: e60.

124.

Tavazzi

Civardi

Caneva

, et al. (2020) Thrombotic events in SARS-CoV-2 patients: an urgent call for ultrasound screening. Intensive Care Medicine 46: 1121–1123.

125.

Cui

Chen

, et al. (2020) Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. Journal of Thrombosis and Haemostasis 18: 1421–1424.

126.

Bader

Manla

Atallah

, et al. (2021) Heart failure and COVID-19. Heart Failure Reviews 26: 1.

127.

Klok

Kruip

MJHA

van der Meer

NJM

, et al. (2020) Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thrombosis Research 191: 145–147.

128.

Zhou

, et al. (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet 395: 1054–1062.

129.

Yang

, et al. (2020) Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory Medicine 8: 475–481.

130.

Arentz

Yim

Klaff

, et al. (2020) Characteristics and outcomes of 21 critically Ill patients with COVID-19 in Washington state. JAMA - Journal of the American Medical Association 323: 1612–1614.

131.

Ruan

Yang

Wang

, et al. (2020) Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Medicine 46: 846–848.

132.

Khan

Karataş

Ceylan

, et al. COVID-19 and therapeutic drugs repurposing in hand: The need for collaborative efforts. Pharmacien Hospitalier et Clinicien. Epub ahead of print June 2020. DOI: 10.1016/j.phclin.2020.06.003.

133.

Pawar

(2020) Combating Devastating COVID-19 by Drug Repurposing. International Journal of Antimicrobial Agents 56: 105984.

134.

Mucke

HAM

(2020) COVID-19 and the drug repurposing tsunami. Assay and Drug Development Technologies 18: 211–214.

135.

Brimacombe

Zhao

Eastman

, et al. (2020) An OpenData portal to share COVID-19 drug repurposing data in real time. bioRxiv 2020.06.04.135046.

136.

Ulm

Nelson

(2020) COVID-19 drug repurposing: Summary statistics on current clinical trials and promising untested candidates. Transboundary and Emerging Diseases tbed.13710.

137.

Glebov

(2020) Understanding SARS-CoV-2 endocytosis for COVID-19 drug repurposing. FEBS Journal febs.15369.

138.

Otomo

Takahashi

Miyoshi

, et al. (2008) Some selective serotonin reuptake inhibitors inhibit dynamin I guanosine triphosphatase (GTPase). Biological & Pharmaceutical Bulletin 31: 1489–1495.

139.

Takahashi

Miyoshi

Otomo

, et al. (2010) Suppression of dynamin GTPase activity by sertraline leads to inhibition of dynamin-dependent endocytosis. Biochemical and Biophysical Research Communications 391: 382–387.

140.

Lin

Singla

Ghoshal

, et al. (2018) Identification of novel macropinocytosis inhibitors using a rational screen of Food and Drug Administration-approved drugs. British Journal of Pharmacology 175: 3640–3655.

141.

Herxheimer

(1949) Antihistamines in bronchial asthma. British Medical Journal 2: 901–905.

142.

Sharma

Sehgal

Sachdeva

, et al. (2019) Direct Engagement of TLR9 Ligand with T Helper Cells Leads to Cell Proliferation & Up-regulation of Cytokines. Immunological Investigations 48: 79–95.

143.

Sanders

Monogue

Jodlowski

, et al. (2020) Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA - Journal of the American Medical Association 323: 1824–1836.

144.

Kouznetsov

(2020) COVID-19 treatment: Much research and testing, but far, few magic bullets against SARS-CoV-2 coronavirus. European Journal of Medicinal Chemistry; 203. Epub ahead of print October 2020. DOI: 10.1016/j.ejmech.2020.112647.

145.

NIH. Antiviral Therapy and Coronavirus Disease COVID-19.

146.

McKee

Sternberg

Stange

, et al. (2020) Candidate drugs against SARS-CoV-2 and COVID-19. Pharmacological Research 57: 104859.

147.

Llitjos

Leclerc

Chochois

, et al. (2020) High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. Journal of Thrombosis and Haemostasis. Epub ahead of print April 2020. DOI: 10.1111/jth.14869.

148.

Tritschler

Mathieu

Skeith

, et al. (2020) Anticoagulant interventions in hospitalized patients with COVID-19: A scoping review of randomized controlled trials and call for international collaboration. Journal of Thrombosis and Haemostasis 18: 2958–2967.

149.

NIH. Immune-Based Therapy and Coronavirus Disease COVID-19.

150.

Chen

Xiong

Bao

, et al. (2020) Convalescent plasma as a potential therapy for COVID-19. The Lancet Infectious Diseases 20: 398–400.

151.

Shen

Wang

Zhao

, et al. (2020) Treatment of 5 Critically Ill Patients with COVID-19 with Convalescent Plasma. JAMA - Journal of the American Medical Association 323: 1582–1589.

152.

Jean

Lee

Hsueh

(2020) Treatment options for COVID-19: The reality and challenges. Journal of Microbiology, Immunology and Infection 53: 436.

153.

Mehta

McAuley

Brown

, et al. (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet 395: 1033–1034.

154.

Monteagudo

Boothby

Gertner

(2020) Continuous intravenous anakinra infusion to calm the cytokine storm in macrophage activation syndrome. ACR Open Rheumatology 2: 276–282.

155.

Abbate

Toldo

Marchetti

, et al. (2020) Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease. Circulation Research 126: 1260–1280.

156.

Shakoory

Carcillo

Chatham

, et al. (2016) Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Critical Care Medicie 44: 275–281.

157.

Dholaria

Bachmeier

Locke

(2019) Mechanisms and management of chimeric antigen receptor T-cell therapy-related toxicities. BioDrugs 33: 45–60.

158.

Zhang

Zhao

Zhang

, et al. (2020) The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologists from China. Clinical Immunology; 214. Epub ahead of print May 2020. DOI: 10.1016/j.clim.2020.108393.

159.

Dixon

Van Tassell

Vecchié

, et al. (2020) Cardiovascular considerations in treating patients with coronavirus disease 2019 (COVID-19). Journal of Cardiovascular Pharmacology 75: 359–367.

160.

Iannaccone

Scacciavillani

Del Buono

, et al. (2020) Weathering the cytokine storm in COVID-19: Therapeutic implications. Cardiorenal Medicine 1–11.

161.

Richardson

Griffin

Tucker

, et al. (2020) Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. The Lancet 395: e30–e31.

162.

Liu

Peng

Qiu

, et al. (2020) Mesenchymal stem cells as a potential therapy for COVID-19. Stem Cell Research and Therapy; 11. Epub ahead of print May 2020. DOI: 10.1186/s13287-020-01678-8.

163.

Leng

Zhu

Hou

, et al. (2020) Transplantation of ACE2- Mesenchymal stem cells improves the outcome of patients with covid-19 pneumonia. Aging Disorder 11: 216–228.

164.

Rajendran

Narayanasamy

Rangarajan

, et al. (2020) Convalescent plasma transfusion for the treatment of COVID-19: Systematic review. Journal of Medical Virology. Epub ahead of print 2020. DOI: 10.1002/jmv.25961.

165.

Bloch

Shoham

Casadevall

, et al. (2020) Deployment of convalescent plasma for the prevention and treatment of COVID-19. Journal of Clinical Investigation 130: 2757–2765.

166.

Rojas

Rodríguez

Monsalve

, et al. (2020) Convalescent plasma in Covid-19: Possible mechanisms of action. Autoimmunity Reviews; 19. Epub ahead of print July 2020. DOI: 10.1016/j.autrev.2020.102554.

167.

Jawhara

(2020) Could intravenous immunoglobulin collected from recovered coronavirus patients protect against covid-19 and strengthen the immune system of new patients? International Journal of Molecular Sciences; 21. Epub ahead of print April 2020. DOI: 10.3390/ijms21072272.

168.

Panyod

Sheen

(2020) Dietary therapy and herbal medicine for COVID-19 prevention: A review and perspective. Journal of Traditional and Complementary Medicine 10: 420–427.

169.

Charan

Bhardwaj

Dutta

, et al. (2020) Use of Complementary and Alternative Medicine (CAM) and Home Remedies by COVID-19 Patients: A Telephonic Survey. Indian Journal of Clinical Biochemistry 1.

170.

Zhou

Dai

Tong

(2020) COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. The Journal of Antimicrobial Chemotherapy. Epub ahead of print March 2020. DOI: 10.1093/jac/dkaa114.

171.

Huang

Song

Huang

, et al. (2020) Pharmacological therapeutics targeting RNA-dependent RNA polymerase, proteinase and spike protein: from mechanistic studies to clinical trials for COVID-19. Journal of Clinical Medicine 9: 1131.

172.

Tang

Liu

Zhang

, et al. (2020) Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies. Frontiers in Immunology 11: 1708.

173.

Devaux

Rolain

Colson

, et al. (2020) New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? International Journal Of Antimicrobial Agents. Epub ahead of print 2020. DOI: 10.1016/j.ijantimicag.2020.105938.

174.

Gautret

Lagier

J-C

Parola

, et al. (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal Of Antimicrobial Agents 105949.

175.

Hawthorn

Kleidon

Larsen

, et al. (2018) Peripheral Intravenous Catheter Protection : British Journal of Nursing 30: 28.

176.

Cortegiani

Ingoglia

Ippolito

, et al. (2020) A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. Journal of Critical Care 57: 279–283.

177.

Wang

Cao

Zhang

, et al. (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research 30: 269–271.

178.

Gao

Tian

Yang

(2020) Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. BioScience Trends; 14. Epub ahead of print 2020. DOI: 10.5582/BST.2020.01047.

179.

Stahlmann

Lode

(2020) Medication for COVID-19-an overview of approaches currently under study. Deutsches Arzteblatt international 117: 213–219.

180.

Mirjalili

Shafiekhani

Vazin

(2020) Coronavirus disease 2019 (COVID-19) and transplantation: pharmacotherapeutic management of immunosuppression regimen. Therapeutics and Clinical Risk Management 16: 617–629.

181.

Cao

Wang

Wen

, et al. (2020) A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19. The New England Journal of Medicine 382: 1787–1799.

182.

Sheahan

Sims

Leist

, et al. (2020) Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nature Communication 11. Epub ahead of print December 2020. DOI: 10.1038/s41467-019-13940-6.

183.

Yao

Qian

Zhu

, et al. (2020) A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—A possible reference for coronavirus disease-19 treatment option. Journal of Medical Virology 92: 556–563.

184.

Baden

Rubin

(2020) Covid-19 - The search for effective therapy. The New England Journal of Medicine 382: 1851–1852.

185.

Martinez

(2020). Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrobial Agents and Chemotherapy; 64. Epub ahead of print May 2020. DOI: 10.1128/AAC.00399-20.

186.

Zeitlinger

Koch

BCP

Bruggemann

, et al. (2020) Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicr. Clinical Pharmacokinetics 1.

187.

Drożdżal

Rosik

Lechowicz

, et al. (2020) FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. Drug Resistance Updates 53: 100719.

188.

Hoffmann

Kleine-Weber

Schroeder

, et al. (2020) SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 181: 271–280.e8.

189.

Hirota

Shimosegawa

Kitamura

, et al. (2020) Continuous regional arterial infusion versus intravenous administration of the protease inhibitor nafamostat mesilate for predicted severe acute pancreatitis: a multicenter, randomized, open-label, phase 2 trial. Journal of Gastroenterology 55: 342–352.

190.

Ragia

Manolopoulos

(2020) Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies. European Journal of Clinical Pharmacology 1.

191.

Santos

Brierley

Gandhi

, et al. (2020) Repurposing therapeutics for potential treatment of SARS-CoV-2: A review. Viruses 12: 705.

192.

Liu

Luo

Libby

, et al. (2020) Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients. Pharmacology and Therapeutics 213: 107587.

193.

Vercauteren

Vandenbroucke

Jones

, et al. (2010) The use of inhibitors to study endocytic pathways of gene carriers: Optimization and pitfalls. Molecular Therapy 18: 561–569.

194.

Han

Ren

, et al. (2020) Advances and challenges in the prevention and treatment of COVID-19. International Journal of Medical Science 17: 1803–1810.

195.

Nitulescu

Paunescu

Moschos

, et al. (2020) Comprehensive analysis of drugs to treat SARS-CoV-2 infection: Mechanistic insights into current COVID-19 therapies (Review). International Journal of Molecular Medicine 46: 467–488.

196.

Baglivo

Baronio

Natalini

, et al. (2020) Natural small molecules as inhibitors of coronavirus lipid-dependent attachment to host cells: A possible strategy for reducing SARS-COV-2 infectivity? Acta Biomedical 91: 161–164.

197.

Irie

Uekama

(1997) Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. Journal of Pharmaceutical Sciences 86: 147–162.

198.

Horowitz

Freeman

(2020) Three novel prevention, diagnostic, and treatment options for COVID-19 urgently necessitating controlled randomized trials. Medical Hypotheses 143: 109851.

199.

Rogosnitzky

Berkowitz

Jadad

(2020). Delivering benefits at speed through real-world repurposing of off-patent drugs: The COVID-19 pandemic as a case in point. JMIR Public Health & Surveillance 6: e19199.

200.

Isidori

Giannetta

Pofi

, et al. (2020) Targeting the NO-cGMP-PDE5 pathway in COVID-19 infection. The DEDALO project. Andrology andr.12837.

201.

Mario

Roberto

Marta

, et al. (2020) Hypothesis of COVID-19 therapy with sildenafil. International Journal of Preventive Medicine; 11. Epub ahead of print 1 January 2020. DOI: 10.4103/ijpvm.IJPVM_258_20.

202.

Mostafa

(2020) Could oral phosphodiesterase 5 inhibitors have a potential adjuvant role in combating COVID-19 infection? Sexual Medicine Reviews. Epub ahead of print 8 September 2020. DOI: 10.1016/j.sxmr.2020.08.006.

203.

Macatangay

BJC

Jackson

Abebe

, et al. (2020) A randomized, placebo-controlled, pilot clinical trial of dipyridamole to decrease human immunodeficiency virus-associated chronic inflammation. Journal of Infectious Diseases 221: 1598–1606.

204.

Al-Tawfiq

Al-Homoud

Memish

ZA.

(2020) Remdesivir as a possible therapeutic option for the COVID-19. Travel Medicine and Infectious Disease. Epub ahead of print March 2020. DOI: 10.1016/j.tmaid.2020.101615.

205.

De Clercq

(2020) Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nature reviews. Drug Discovery 19: 149–150.

206.

Grein

Ohmagari

Shin

, et al. (2020) Compassionate use of remdesivir for patients with severe Covid-19. The New England Journal of Medicine 382: 2327–2336.

207.

Beigel

Tomashek

Dodd

, et al. (2020) Remdesivir for the Treatment of Covid-19 — Preliminary Report. The New England Journal of Medicine. Epub ahead of print May 2020. DOI: 10.1056/nejmoa2007764.

208.

R P Tomkiewicz 1 et al. Amiloride Inhalation Therapy in Cystic Fibrosis: Influence on Ion Content, Hydration, and Rheology of Sputum and American Review of Respiratory Disease.

209.

Liu

Zhou

, et al. (2020) Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Central Science 6: 315–331.

210.

Xinhua. Favipiravir shows good clinical efficacy in treating COVID-19: official - Xinhua and English.news.cn.

211.

Horby

Lim

Emberson

, et al. (2020) Effect of dexamethasone in hospitalized patients with COVID-19: Preliminary report. medRxiv 2020.06.22.20137273.

212.

Russell

Millar

Baillie

(2020) Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. The Lancet 395: 473–475.

213.

Jamilloux

Henry

Belot

, et al. (2020) Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmunity Reviews; 19. Epub ahead of print July 2020. DOI: 10.1016/j.autrev.2020.102567.

214.

Rizk

Kalantar-Zadeh

Mehra

, et al. (2020) Pharmaco-immunomodulatory therapy in COVID-19. Drugs 1.

215.

Prete

Favoino

Catacchio

, et al. (2020) Sars-cov-2 inflammatory syndrome. Clinical features and rationale for immunological treatment. International Journal of Molecular Sciences; 21. Epub ahead of print May 2020. DOI: 10.3390/ijms21093377.

216.

Chakraborty

Sharma

, et al. (2020) SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): Diagnostic and proposed therapeutic options. European Review for Medical and Pharmacological Sciences 24: 4016–4026.

217.

Allegra

Innao

Allegra

, et al. (2020) Coagulopathy and thromboembolic events in patients with SARS-CoV-2 infection: pathogenesis and management strategies. Annals of Hematology 1.

218.

Alhazzani

Lim

Jaeschke

, et al. (2013) Heparin Thromboprophylaxis in Medical-Surgical Critically Ill Patients. Crit Care Medicine 41: 2088–2098.

219.

Chistolini

Ruberto

Alessandri

, et al. (2020) Effect of low or high doses of low-molecular-weight heparin on thrombin generation and other haemostasis parameters in critically ill patients with COVID-19. British Journal of Haematology 190: e214–e218.

220.

Kharma

Roehrig

Shible

, et al. Anticoagulation in critically ill patients on mechanical ventilation suffering from COVID-19 disease, the ANTI-CO trial: A structured summary of a study protocol for a randomised controlled trial. Trials; 21. Epub ahead of print 7 September 2020. DOI: 10.1186/s13063-020-04689-1.

221.

Lemos

ACB

do Espírito Santo

Salvetti

, et al. (2020) Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID). Thrombosis Research 196: 359–366.

222.

Muthuraman

Al Haziazi

(2020) COVID-19 Impact on Health, Social & Economy. International Journal of Nutrition, Pharmacology, Neurological Diseases 10: 159–160.

223.

Subramanian

Mohamed

Khanzadah

(2020) The Corona virus’ Impact on Education − School Students’ Perspective. International Journal of Nutrition, Pharmacology, Neurological Diseases 10: 166–167.

224.

Fernandes

(2020) Impact of COVID-19: University students’ perspective. International Journal of Nutrition, Pharmacology, Neurological Diseases 10: 168–169.

225.

Al-Balushi

Essa

(2020) The impact of COVID-19 on children − parent’s perspective. International Journal of Nutrition, Pharmacology, Neurological Diseases 10: 164–165.

226.

Prabhakar

Punnaveetil

(2020) COVID-19 Impact − A Physician’s Perspective. International Journal of Nutrition, Pharmacology, Neurological Diseases 10: 161–163.

227.

Essa

Hamdan

Chidambaram

, et al. (2020) Possible role of tryptophan and melatonin in COVID-19. International Journal of Tryptophan Research 13: 1–2.